# Merck & Co vs Novartis: valuation, size and margins compared

URL: https://funkfolio.com/compare/mrk-vs-nvs

> Merck & Co ($353.4B, P/E 145) and Novartis ($300.5B, P/E 30.6) compared: size, valuation, margins, debt, cash and price change.

---

## Merck & Co vs Novartis

Merck & Co (MRK), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Merck & Co is worth $353.4B on the stock market and Novartis $300.5B: Merck & Co is valued at 18% more. Merck & Co trades at 145 times earnings and Novartis at 30.6. Over the past year Merck & Co's share price has moved +49.8% and Novartis's +25.1%.

### Key facts

- **Merck & Co market value:** $353.4B
- **Novartis market value:** $300.5B
- **Merck & Co P/E:** 145
- **Novartis P/E:** 30.6
- **Merck & Co revenue:** $65B FY to 2025-12-31
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Superinvestors holding both:** 8

Market values as of 18 Nov 2026, 04:05 UTC.

Merck & Co vs Novartis: every measure side by side

| Measure | Merck & Co | Novartis |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Switzerland |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $353.4B higher | $300.5B lower |
| Revenue | $65B higher | $54.5B lower |
| Earnings | $18.3B higher | $14B lower |
| Employees | 73,000 lower | 75,267 higher |
| Total assets | $136.9B higher | $110.9B lower |
| Valuation |  |  |
| P/E | 145 higher | 30.6 lower |
| P/S | 5.4 lower | 5.5 higher |
| P/B | 7.9 | — |
| Dividend yield | 2.33% | — |
| Profitability |  |  |
| Operating margin | — | 32.4% |
| Balance sheet |  |  |
| Net assets | $52.6B higher | $46.1B lower |
| Total liabilities | $84.2B higher | $64.4B lower |
| Total debt | $49.3B higher | $28.7B lower |
| Cash on hand | $14.6B higher | $11.4B lower |
| Price change |  |  |
| Today | -0.75% lower | -0.67% higher |
| 1 year | +49.8% higher | +25.1% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Merck & Co 154.4, Novartis 121.0.

- Merck & Co (MRK)
- Novartis (NVS)

Merck & Co and Novartis share prices over one year, rebased to 100: Merck & Co ends at 154.4, Novartis at 121.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | MRK | NVS |
| --- | --- | --- |
| Nov 28, 2025 | 112.9 | 99.1 |
| Dec 31, 2025 | 113.4 | 104.8 |
| Jan 30, 2026 | 118.7 | 113.0 |
| Feb 27, 2026 | 133.3 | 128.2 |
| Mar 31, 2026 | 129.5 | 116.1 |
| Apr 30, 2026 | 117.6 | 112.4 |
| May 29, 2026 | 127.8 | 114.2 |
| Jun 30, 2026 | 138.4 | 119.1 |
| Jul 31, 2026 | 140.2 | 118.7 |
| Aug 31, 2026 | 159.1 | 115.6 |
| Sep 30, 2026 | 156.5 | 108.4 |
| Oct 30, 2026 | 161.0 | 122.2 |
| Nov 17, 2026 | 154.4 | 121.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (8)

- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 4.9% / 0.3%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 1.7% / 0.7%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.6% / 0.1%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 1.5% / 0.2%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.2% / 0.4%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / &lt;0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / 0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / &lt;0.1%

#### Merck & Co only (15)

- [Bill Smead](https://funkfolio.com/gurus/bill-smead) 7.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) 2.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 2.0%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.4%
- [Prem Watsa](https://funkfolio.com/gurus/prem-watsa) 0.9%
- [Christopher Bloomstran](https://funkfolio.com/gurus/christopher-bloomstran) 0.6%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.6%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 0.5%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.4%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.3%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%

#### Novartis only (5)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.8%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.6%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.3%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.2%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Merck & Co / Novartis). [Who owns MRK](https://funkfolio.com/stock/MRK/superinvestors) · [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors)

### More on Merck & Co

- [Merck & Co (MRK) stock page](https://funkfolio.com/stock/MRK)
- [Merck & Co market cap](https://funkfolio.com/stock/MRK/market-cap)
- [Merck & Co revenue](https://funkfolio.com/stock/MRK/revenue)
- [Merck & Co P/E ratio](https://funkfolio.com/stock/MRK/pe-ratio)
- [Merck & Co operating margin](https://funkfolio.com/stock/MRK/operating-margin)
- [Merck & Co total debt](https://funkfolio.com/stock/MRK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Merck & Co against its closest peers

- [Merck & Co vs UnitedHealth Group](https://funkfolio.com/compare/mrk-vs-unh)
- [Merck & Co vs AbbVie](https://funkfolio.com/compare/abbv-vs-mrk)
- [Merck & Co vs AstraZeneca](https://funkfolio.com/compare/azn-vs-mrk)

#### Novartis against its closest peers

- [Novartis vs AstraZeneca](https://funkfolio.com/compare/azn-vs-nvs)
- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Thermo Fisher Scientific](https://funkfolio.com/compare/nvs-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Merck & Co or Novartis?**

By market value, Merck & Co is the larger: $353.4B against $300.5B for Novartis. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $54.5B for Novartis.

**Which has the higher P/E ratio?**

Merck & Co: 145, against 30.6 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has more debt?**

Merck & Co: $49.3B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Merck & Co and Novartis?**

In their latest 13F filings, Thomas Kahn, Ken Fisher, Jeremy Grantham (co-founder), Charles Brandes (founder), Brandon Haley, Murray Stahl, Dodge & Cox team and Rajiv Jain hold both.

### Cite this page

Funkfolio, “Merck & Co vs Novartis”, data as of 18 November 2026. https://funkfolio.com/compare/mrk-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
